Your browser doesn't support javascript.
loading
Clearance of Hepatitis B e Antigen in Untreated Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-analysis.
Mohareb, Amir M; Liu, Anne F; Kim, Arthur Y; Coffie, Patrick A; Kouamé, Menan Gérard; Freedberg, Kenneth A; Boyd, Anders; Hyle, Emily P.
Afiliación
  • Mohareb AM; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Liu AF; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Kim AY; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Coffie PA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Kouamé MG; Division of Gastroenterology, Hepatology, and Endoscopy, Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Freedberg KA; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Boyd A; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Hyle EP; Department of Dermatology and Infectious Diseases, UFR des Sciences Médicales, Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire.
J Infect Dis ; 226(10): 1761-1770, 2022 11 11.
Article en En | MEDLINE | ID: mdl-35511194
BACKGROUND: In people with hepatitis B virus (HBV) infection, persistence of hepatitis B e antigen (HBeAg) is associated with clinical progression and need for treatment. HBeAg loss represents partial immune control and is a critical event in the natural history of chronic HBV. METHODS: We conducted a systematic review and meta-analysis of cohort studies that report HBeAg loss among people with untreated chronic HBV. We evaluated HBeAg loss using a random-effects model and conducted subanalysis on region. RESULTS: We screened 10 560 publications, performed 196 full-text analyses, and included 26 studies for meta-analysis. The pooled rate of HBeAg loss was 6.46/100 person-years (PYs) (95% confidence interval, 5.17-8.08). Meta-regression showed that older age of participants and studies in Europe were associated with higher rate of HBeAg loss. Rates per 100 PYs were 7.43 (95% confidence interval, 6.30-8.75; 1 study) in Africa, 3.24 (2.61--4.02; 1 study) in the Eastern Mediterranean, 13.67 (11.21-16.66; 4 studies) in Europe, 7.34 (4.61--11.70; 5 studies) in North America, and 5.53 (4.05--7.55; 15 studies) in the Western Pacific. CONCLUSIONS: Spontaneous HBeAg loss occurs at a rate of 6.46/100 PYs. Variations by region and age group may reflect epidemiological, immunological, or HBV genotype-related differences.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatitis B Crónica / Hepatitis B Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: J Infect Dis Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatitis B Crónica / Hepatitis B Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: J Infect Dis Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos